Fixed or weight-adjusted dosis of enoxaparin as prophylaxis for venous thromboembolism in acutelly ill medical patients Source: Eur Respir J 2004; 24: Suppl. 48, 273s Year: 2004
Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007
Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children Source: Eur Respir J, 57 (1) 2001756; 10.1183/13993003.01756-2020 Year: 2021
Cessation of combination therapy for asthma during pregnancy Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
The efficacy, safety and tolerability of the short 12-month pre-XDR-TB regimen regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase Source: International Congress 2017 – Paediatric TB: MDRTB (II) Year: 2017
Efficacy and safety of treatment with anticoagulants in patients with unprovoked venous thromboembolism in Korea Source: International Congress 2016 – Acute pulmonary embolism Year: 2016
Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021
Effect of daily azithromycin therapy and adherence on readmission risk in COPD Source: Eur Respir J, 53 (3) 1801377; 10.1183/13993003.01377-2018 Year: 2019
Efficacy of oral add-on therapy in patients with pulmonary hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009
Clinical efficacy of bolus versus continuous-infusion of piperacillin-tazobactam in VAP treatment Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011
The efficacy, safety and tolerability of the short 12-month MDR-TB regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now? Year: 2017
Direct oral anticoagulants and low-molecular weight heparin for primary prevention of venous thromboembolism in cancer patients: a meta-analysis Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism Year: 2020
Efficacy and safety of systemic and prolonged low-dose thrombolysis in thromboembolic disease Source: Eur Respir J 2002; 20: Suppl. 38, 478s Year: 2002
Adverse drug reactions and outcomes of tuberculosis treatment using fixed-dose combination (FDC) regimen Source: Annual Congress 2012 - Tuberculosis: clinical findings I Year: 2012
Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Prolonged anticoagulation in VTE with direct oral anticoagulants: towards an individual analysis of net clinical benefit? Source: Eur Respir J 2016; 48: 1268-1270 Year: 2016
Comparison of two regimens of oral anticoagulation in pulmonary embolism Source: Eur Respir J 2006; 28: Suppl. 50, 632s Year: 2006
One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 618s Year: 2004
Management of bleeding during anticoagulant therapy Source: International Congress 2019 – Update on anticoagulant therapy: controversy and progress Year: 2019